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CHAPTER 1
Basics of Radiotherapy
1.1 Introduction
Radiotherapy is a type of cancer treatment that uses ionizing radiation to control
malignant cells for either curative or palliative purpose. The root of radiotherapy can be
traced back to more than 100 years ago shortly after x-ray was discovered. In the first few
decades radioactive isotopes were used as the source of radiation in radiotherapy. The
limitation of using radioactive isotopes is that the energy is too low and thus the depth of
penetration is shallow.1 In order to treat deep tumors without surgery, source of high
energy x-rays became a demand. In the 1950s, the first megavoltage medical linear
accelerator was build at Stanford University which opened the new era of radiotherapy. 2
Over the past half century, multiple technologic revolutions in radiotherapy have resulted
in better treatment outcomes and fewer side effects. In 2000, one in every two cured
cancer patient are treated or partially treated with radiotherapy.2 Radiotherapy has become
one of the most effective and widely used methods for cancer treatment.
In modern radiotherapy, the process starts from computerized tomography (CT)
simulation, where volumetric CT data of the patient is acquired. Magnetic resonance
images (MRI) are also commonly used, especially for brain tumors. Based on the images,
commercial treatment planning system (TPS) is used to create a radiotherapy treatment
plan. Once the plan is approved and verified, the radiotherapy treatment of the patient can
be initiated. The total prescription dose is usually divided into many fractions and the
patient normally gets one fraction per day, so the entire treatment course may take weeks.
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Two primary components of radiotherapy are planning and delivery. If a plan can achieve
very good tumor coverage and spare normal organs, but the delivery system is unable to
deliver the plan to patient, the beautiful plan becomes useless. On the other hand, if the
delivery system is very robust but the TPS is very limited and unable to generate an
acceptable plan, the robust delivery system is a waste. Thus the development of both
planning systems and delivery systems is of paramount importance and the development of
both systems is often intertwined.

1.2 Development of Treatment Planning and Delivery
Since radiation can damage both malignant cells in tumors and also normal tissue
cells, careful treatment planning and appropriate treatment techniques are required to
minimize damage to normal tissue while eradicating tumor cells. Before the era of three
dimensional conformal radiotherapy, two dimensional x-ray images were used to align
radiation beams to the target. The precision of treatment was relatively poor due to the fact
that the target shape was not fully visualized. Because the planning was based on our
guess of the target shape, large margins had to be added to assure that the entire tumor was
in the radiation field, and therefore significant doses were delivered to normal tissues. In
order to prevent significant complications, the prescription dose was limited.
After the invention of 3D imaging such as CT and MRI, 3D digitally reconstructed
radiographs were introduced into the radiotherapy treatment planning process.

These

digitally reconstructed radiographs are obtained in the form of closed spaced transverse
images and can be processed to reconstruct anatomy in any plane.

Thus the most

significant improvement over 2D planning was that any structure could be reconstructed
and viewed in any direction. Radiation beams could then be shaped at selectable angles
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using beam eye‟s view such that the tumors received radiation dose and organs-at-risk
(OAR) are spared. This is called 3D conformal radiotherapy (3D CRT). Because we can
see the shape of the target, the margins can be reduced. Compared to 2D planning, 3D
CRT is much more precise and generally reduces radiation dose to critical organs that
surround the target.

Field 1

Field 2

Figure 1: Illustration of relative locations of structures that are relevant in a prostate
cancer radiotherapy treatment. Red structure: target which includes prostate, possible subclinical disease extensions and necessary margins; yellow structure: bladder; Brown
structure: rectum; white structures: femoral heads. Field 1 and Field 2 are two beams that
completely avoid the normal structures.

Although digitally reconstructed radiographs allow us to view anatomy in any plane
and at any angle, there are still obstacles that prevent us from limiting dose to critical
organs or increasing dose to target structures. Take prostate cancer treatment for example.
The organ contours and their relative locations are illustrated in Figure 1. Field 1 and Field
2 are two possible beam directions that avoid normal organs. As shown in the figure, it is
impossible to deliver radiation dose to the entire target without irradiating normal organs.
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Field B
Field A

Figure 2: Illustration of relative locations of structures that are relevant in a prostate
cancer radiotherapy treatment. Red structure: target which includes prostate, possible subclinical disease extensions and necessary margins; yellow structure: bladder; Brown
structure: rectum; white structures: femoral heads. Field A and Field B are two probable
beams that can enclose the target volume.
So we have to pass radiation beams through normal organs (Figure 2). But we must ensure
that the doses to normal organs are minimized and below their tolerance so that the
treatment won‟t cause significant normal tissue complication. In 3D CRT, radiation fields
that are aligned to the shape of target are open during the treatment. The output (intensity)
from the linear accelerator is roughly constant across the field. If we neglect attenuation
differences inside the patient‟s body, the dose to the normal organs would be the same as
the dose to the target that sits at the same depth. In this prostate case, significant doses
would be delivered to rectum. In order to reduce the dose to rectum, one can reduce the
radiation intensity in the portion of the field where the rectum sits. The intensity from
another field can then be increased in this region to compensate for this reduction in dose
from the first field. This leads to the concept of intensity modulation and Intensity-
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Modulated Radiotherapy (IMRT). Figure 3 is a simple sketch that illustrates such intensity
modulation. In real radiotherapy planning, the modulation is much more complex because
of numerous dose-volume constraints for multiple structures.

Figure 3: Illustration of intensity modulation.

IMRT is a major technologic development over conventional radiotherapy. It is
arguably the most important revolution in radiation oncology. The first use of IMRT
appeared in the beginning of 1990s and it became popular from the mid 1990s. The
implementation of IMRT delivery techniques has resulted in significant reduction in
absorbed dose to OARs compared to 3D CRT
complication probability (NTCP).7-10

3-6

, and this leads to lower normal tissue

Alternatively, this increased conformity can be

exploited by escalating the dose to the target to achieve higher tumor control probability
(TCP) while maintaining OAR doses below their tolerance.11-13 It should also be noted that
changes in the delivery technique can significantly change the absorbed dose throughout
the patient, and not just in the vicinity of the target structure(s). For example, in the study
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reported by D.B. Mansur et al

14

, the authors found that compared to 3D CRT, IMRT

treatment resulted in lower peripheral dose in regions closer to the target. However, at
distant points, IMRT deposited more dose than 3D CRT presumably due to IMRT‟s higher
monitor units and increased head leakage.
One of the most important components commonly employed for IMRT is the
inverse planning system. Conventionally in forward planning, one would subjectively
define or design the direction and the number of fields, the shape of each field, the margins
that need to add to target, the relative weighting of the fields, the use of wedges or
compensators, etc. After dose calculation, the user then evaluates the planning results and
decides what changes are needed in order to achieve the desired planning goals. It is an
iterative process performed until the planning results are satisfactory. In inverse planning
systems, the planner defines the number and the angles of the fields and then starts from
the planning goals. For each structure, a set of constraints are defined. These constrains
limit the dose levels to certain percentages of the structure volume (Figure 4). Then the
computerized optimizer will find a solution that satisfies the constraints (planning goals) to
the maximum extent possible. Each field can be viewed as consisting of many beamlets.
Intensity modulation is achieved by varying the individual intensities of each beamlet. The
Multi-Leaf Collimator (MLC) is a device commonly used for shaping radiation fields and
is most often the method used to modulate the beamlet intensities during delivery of IMRT
(Figure 5).
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Figure 4: Optimization screenshot in Eclipse treatment planning system. Planner defines a
set of constraints for relevant structures.

8

Figure 5: Multi-leaf collimator (MLC). Top: a simple illustration. Bottom: MLC in a
Varian linear accelerator.
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As mentioned earlier, development of technologies results in lower dose to critical
organs, smaller margins added to tumor site, and dose escalation to target. All these
advancements require that the dose be accurately delivered to the right location.

In

radiotherapy, the prescription dose is usually delivered in multiple days with the exception
of stereotactic radiosurgery in which the dose is delivered in one fraction. Each treatment
is called one fraction. The entire treatment course may take up to 8 or 9 weeks. If the
setup is perfect everyday and the structures and/or cells do not migrate, the job of
predicting the effect of radiation dose would be easier. However, those are not true. Not
only is the day-to-day setup not perfect, but also the organs move during a fraction (intrafraction motion) and in between fractions (inter-fraction motion).15-19 In the work by B.
Kihlbn et al 15, treatment variations were studied for various cancer sites. Notable errors of
9mm were found for esophagus, followed by 7mm for breast and ovaries. Prostate is also
an organ that is known to move around and could displace by over 10mm.20-21 In lung
tumor treatment, respiratory motion is usually an issue that needs to be taken into account
during planning.22-23 All these facts suggest that we need to track the inter-fraction and
intra-fraction movements of organs during the delivery of radiation.

This led to the

development of Image-Guided Radiotherapy (IGRT).
IGRT enables us to see the location of the target or organs right before the
treatment or during the treatment, which prevents large deviations in the planned dose.
Better image guidance technology allows clinicians to potentially reduce PTV margins
which then provides increased latitude within which to capitalize on the more conformal
dose distributions offered by more sophisticated delivery techniques. However, reduced
margins result in the potential hazard of a geographical miss if the capabilities of image
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guidance and immobilization are overestimated.24 In such cases, the target dose may be
significantly reduced which may also be accompanied by a significant increase in OAR
doses.
In addition, IGRT techniques involving ionizing radiation introduce additional
patient dose from the imaging technique prior, during, or after treatment.25 The additional
dose introduced is typically at the order of a few centi-grays (cGy) for one fraction of
treatment. Compared to the therapeutic dose which is on the order of a few grays (Gy)
(1Gy = 100cGy), this is a very small amount and the effect is usually neglected. But since
the entire treatment course could be composed of more than 40 fractions, the total imaging
dose could become significant in comparison to the therapeutic fraction dose if daily
imaging guidance employed.25 Several studies have shown that the administration of low
doses prior to radiation therapy may result in a detrimental effect by accelerating tumor
cell proliferation and increasing tumor radioresistance.25-26 Furthermore, an experiment by
H.P. Bijl et al

27

showed unexpected organ tolerance dose changes due to a low

background bath dose, providing an additional indication that relatively small imaging
doses before or during treatment might have deleterious effects to normal tissues. So the
dose introduced by IGRT might bring double-trouble to radiotherapy treatment: 1) it may
increase the tumor‟s resistance to radiation, and 2) it may decrease the normal tissue‟s
tolerance to radiation.

Therefore, when administering ionizing radiation for image

guidance, the biological effect of the imaging dose needs to be considered and investigated.
Another fact that limits the precision of depositing dose to a designated location is
that cells could migrate. The study by R. Franklin et al reported a 2mm migration of
remyelinating cells.28

Such a 2mm movement could be extremely important for
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stereotactic radiosurgery which aims at achieving sub-millimeter accuracy.29-31

This

distance is also comparable to the reported accuracy of modern IGRT techniques.32-33 The
effect of cell migration is an effective smearing of dose distributions. The effects of this
smearing has been presented by Y. Huang et al.34 In some important aspects, we are
approaching the physical limits of our ability to make radiotherapy dose distributions more
conformal. We must also begin to consider the biological effects of new radiotherapy
technologies and the associated uncertainties in these biological effects as these may
become significant and could potentially offset some gains made by physical and technical
advantages.

1.3 Limitations of Current Treatment Planning Systems
Inverse planning systems were developed to optimize and evaluate treatment plans
based on physical dose-volume constraints.

Before this work was started, the only

commercial treatment planning system that incorporated some biological information in
the optimization process was the P3IMRT® TPS by Philips.

In this system, plan

optimization is performed using generalized equivalent uniform dose (gEUD, will be
discussed later) constraints and objective functions originally derived for the ORBIT ®
system.35 Eclipse (Varian Medical Systems, Inc.) is another commonly used treatment
planning system. For convenience, this work has been developed and tested with the
Eclipse system since this system is available in our department. But the application of this
work is not limited to the Eclipse system.
The optimization in the Eclipse system is done inversely by selecting a limited set
of dose-volume constraints input by the treatment planner as show in Figure 4. The
planner chooses appropriate upper and lower limits for different structures and set
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preferred priorities and other parameters. Then the Eclipse TPS tries to calculate an
optimum plan that satisfies the planner‟s objectives. The fact is that the solution to the
optimization objective function is not unique and the final plan created by the planning
system is just a single possibility from a tremendously large set of possible solutions. The
question remains as to what makes this the “optimum” plan for this patient and what
information is utilized in making such a decision. Treatment plans are evaluated mainly
based on dose-volume histograms (DVHs) (Figure 6). Ideally, a perfect plan would deliver
the full prescription dose to the planning target volume (PTV) and no dose to the OARs.
That is, as shown in Figure 6, to push the PTV curve (the purple line) to the upper right
corner and the OAR curves (blue, brown and green lines) to the lower left corner as much
as possible.
The term “optimization” is in fact inappropriate for the current state of inverseplanned IMRT, as it implies both that we know what the optimum plan is, and that we are
actually capable of achieving that plan.36 A treatment plan should not be characterized as
“optimized” as a result of the minimization of an objective function using a limited set of
parameters input by the treatment planner. This is particularly true if these objectives are
based solely on physical dose. The vast majority of IMRT treatment plans currently
delivered to patients (and termed “optimized”) takes only physical dose information into
account. Not considering biological information clearly prohibits any effort to create truly
“optimized” plans in terms of patient outcome.
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Figure 6: Dose Volume Histograms (DVH) in Eclipse treatment planning system.
Treatment plans in Eclipse are currently evaluated based on DVHs, which
essentially eliminates all spatial information associated with the dose distribution. In
IMRT planning, as plan complexity increases, the dose heterogeneity can be significant.
Thus the spatial dose distribution inside a structure becomes important, especially when
"cold" spots (under-dosed regions) or “hot” spots (over-dosed regions) are present.37-39
The DVH provides simple dose volume coverage information in a single plot and is widely
used as an indicator of plan quality.40-41 However, IMRT optimization based on aspects of
the DVH does not tell the planning system where in a given structure to allow or prevent
the "cold" or “hot” spots. Thus, if significant "cold" spots are located in the center of the
gross disease, a plan with sharper fall-off in the target DVH might not be better than a plan
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with shallower fall-off DVH. Similarly, different distributions of “hot” spots may also lead
to different outcomes.39 As a result, the clinician still must review the 3D dose distribution
during the plan evaluation process since the DVH contains no spatial information.
The 3D dose distribution information can only be viewed in one 2D plane at a time
making it more difficult for the observer to objectively quantify plan quality. Moreover, it
is only a static snapshot of what the delivered plan would look like on the CT data acquired
at the time of simulation. However, in a real radiotherapy treatment process, the presence
of setup uncertainties42, interfraction and intrafraction motion21, and underlying cell
migration43 will mean that the dose to any individual component of tissue in the patient
will differ from the static dose observed in the treatment planning system. Ideally, the
effects of these should be included in the plan evaluation process prior to selecting the
desired treatment plan and attempting to estimate its effects.
Furthermore, fractionation sensitivity (quantified by the α/β ratio) varies among
cells from site to site and/or from patient to patient.44 Therefore, not only will the static
dose distribution viewed within the treatment planning system differs from the absorbed
dose distribution received by the patient throughout the course of radiotherapy, but the
physical dose distribution may not be the best representation of the plan quality since it
does not contain any of the biological information which is important in determining the
outcome of treatment. Biological parameters need to be included when evaluating or
optimizing a radiotherapy plan. Cells may react to radiation differently (Figure 7).44 In
other words, a physical dose of 2Gy would not cause the same level of cell killing for
different cells or organs. An effective or equivalent dose that takes the sensitivity into
account is desirable.
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Figure 7: Radiosensitivity varies between different cell lines (Ref. 44).
Experimental results show that many organs have a strong volume effect.45 Such
organs will have different tolerance doses when differing amounts of the organ are
irradiated. In Figure 8, the four curves from left to right are response curves for 20mm,
8mm, 4mm and 2mm of rat cervical spinal cord after proton irradiation, respectively.45 By
decreasing the irradiated length from 20mm to 2mm, the 50% responder dose increased
from about 20 Gy to nearly 90 Gy, which is over 4 times higher. Moreover, this group did
further research and found that the distribution of the doses has significant influence on
radiation response of rat cervical cord (Figure 9).27 The two 4mm segments irradiated has
much higher tolerance dose than a single 8mm segment. These facts confirm that the
spatial information for a radiotherapy plan must be taken into account when assessing a
radiotherapy treatment plan.
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Figure 8: Rat spinal cord showed strong volume effect (Ref. 45)

Figure 9: Rat spinal cord response curve shifts in the split-field irradiation experiment
reported by H.P. Bijl et al (Ref. 27).

17

Figure 10: Increased radioresistance from A to B induced by hypoxia (Ref. 44).

Hypoxia is another important factor that may introduce great uncertainty in
predicting the outcomes of a radiotherapy plan. It is assumed that the more severe the
hypoxia is in a tumor, the more radioresistant the tumor will be. For example in Figure 10,
from line A to B, the concentration of oxygen is reduced by replacing air with nitrogen.
The dose required to induce a survival fraction of 0.1 for B is about three times higher than
that for A.44 Thus, knowledge of whether hypoxia is present in a tumor and its extent
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becomes critical to a radiotherapy treatment.
Tumor cell proliferation also needs to be taken into consideration because IMRT
radiotherapy treatment course may take up to 8 or 9 weeks. Many studies about tumor
repopulation during the course of radiotherapy have been published.46-52 For a head-neck
cancer treatment that takes longer than four weeks, the effect of cell proliferation is
equivalent to a loss of radiation dose of about 0.6 Gy/day.46 The article by R. Tarnawski et
al concludes that accelerated repopulation could start after two weeks of treatment, and
during treatment gap there is effectively 0.75 Gy/day loss while during irradiated days the
loss is 0.2 Gy/day.47 A clinical study for cervical cancer was reported by J.Z. Wang et al.48
They found the predicted onset time for cell repopulation for cervical cancer was 19 days.
In vivo experiments performed by R.E. Durand et al indicates that tumor cell proliferation
may start after only a few fractions of radiation exposure in human tumor xenografts. 49
Additionally, their results suggest that pretreatment potential doubling time values may
underestimate the actual re-growth rate. For non-small-cell lung cancers, an association
between overall treatment time and outcomes is found on the multivariate analysis and
survival outcomes are better with shorter treatment time.50 For treatments beyond six
weeks, a notable loss of survival rate of 1.6% per day is observed, which corresponds to a
time-dose tradeoff of 0.6-0.8 Gy/day at 2 Gy fraction size.51 Although prostate cancer is
considered a slow growing tumor and the influence of tumor repopulation is not as
significant as the aforementioned sites, a correlation is found between the overall treatment
time and the treatment outcomes by D.J. D'Ambrosio et al.52 In their study, the nontreatment day ratio (NTDR), which is defined as the number of non-treatment days divided
by the total elapsed days of treatment, is found to be a statistically significant predictor of

19

biochemical failure for low-risk prostate cancer patients who mostly had local-only
diseases. Proliferation of prostate tumor begins at some time less than 52 days and the
dose required to offset the extended treatment is about 0.24Gy/day.53

These studies

indicate that dose escalation would be needed to compensate for the dose loss due to the
accelerated tumor cell proliferation. However, dose escalation would also increase the
dose to normal tissues which could result in higher complication rate.
TCP (tumor control probability) and NTCP (normal tissue complication probability)
are commonly calculated to evaluate treatment plans in addition to static dose and
DVHs.54-58 The aim of such calculations is to incorporate some radiobiological parameters
and distill the 3D dose information into a single metric or a handful of metrics to be used
for plan evaluation and comparison. Generalized equivalent uniform dose (gEUD) 59-60 is a
common approach which incorporates certain tissue specific parameters and attempts to
account for volume effects
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in radiotherapy. Unfortunately, most studies or tools

calculate gEUD and then TCP or NTCP from DVH data distilled from static dose
distributions.37,

61-65

As discussed previously, the dose distribution calculated by the

treatment planning system is in general not a true representation of the actual absorbed
dose distribution or the biologically effective dose distribution, and the use of the DVH
inherently eliminates all spatial dose information.
To compensate for the lack of spatial information within the DVH, supplemental
methods of representation have been proposed.66-67 C.W. Cheng et al developed zDVH
which is defined as a differential dose–volume histogram with respect to a CT slice
position.66 Instead of using one dose-volume curve for a 3D target in the current format of
DVH, they decompose it into multiple curves with each representing one isodose level.
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Thus they are able to incorporate the axial spatial information by plotting percentage
volume with respect to the CT slice location for each isodose level. But within each slice,
"cold" or "hot" spot locations are still unknown. Later, K.S. Chao et al introduced a
conceptual method to integrate spatial dose information into dose-volume scoring-function
histograms (DVSH).67 A scoring function which represents the distance from the gross
tumor volume (GTV) edge to the clinical target volume (CTV) edge is used. DVSH plots
the dose (vertical scale) and the volume (on a color scale) against the score (horizontal
scale). Thus at each score (a spatial location), one can read the dose range and the volume
that each dose level occupies. However, DVSH not only looks totally different from DVH
format but also uses a color scale for the volume size, which makes it less intuitive than the
simple DVH concept.
In conclusion of all the aforementioned discussions, the spatial and biological
information should also be taken into account in treatment evaluation and optimization
process. Many software tools have been developed to incorporate biological information
into the radiotherapy treatment planning and/or evaluation process.61, 63-65, 68-71 And during
the years of developing this work, other commercial planning systems such as Eclipse and
Monaco (Elekta, Stockholm, Sweden) also added biological optimization and evaluation
modules. Although each of these tools or systems offers different and useful features for
plan analysis, most of them do not retain biological information at the voxel level which
limits their ability to preserve the spatial information. In fact, none of them provides
computerized algorithms to optimize spatial dose distributions within a specific structure.
Here I present a new treatment plan evaluation tool called SABER (Spatial And Biological
Evaluation for Radiotherapy) which not only provides standard biological plan evaluation
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but also transforms physical doses at the voxel level and incorporates both HRS and spatial
information. In addition, the software can incorporate hyperradiosensitivity (HRS, will be
discussed later) into the plan evaluation. In the next session, I will outline the methods and
models we used for the project.
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CHAPTER 2
Methods and Modeling
Both spatial and biological information are necessary in order to perform true
optimization of a treatment plan and for predicting clinical outcome. The SABER software
system overcomes some limitations of the current commercial planning systems.

It

provides spatial and biological plan evaluation. It incorporates hyperradiosensitivity using
the induced-repair model and applies the new concept of Dose Convolution Filter to
simulate dose wash-out effects due to cell migration, bystander effect, and tissue motion
during treatment. Further, Spatial DVH (sDVH) is introduced to evaluate the spatial dose
distribution in the target volume. Finally, generalized equivalent uniform dose is derived
from both physical dose distribution (gEUD) and EQD2 distribution (gEUD2), and the
software provides three models for calculation of TCP, NTCP, and Complication-free TCP
(P+).

2.1 Retaining Spatial Information
2.1.1 Dose Convolution Filter
When inhomogeneous doses are present, any relative change in the location of a
particular volume element of tissue with respect to the delivered dose distribution will
result in changes to the dose received by that volume element. Tissue in a higher dose
region in one fraction may reside in a lower dose region in another fraction. The concept
of PTV is developed to compensate for uncertainties in the location of a structure by
adding a margin to the clinical target volume (CTV). However, applying the PTV in the
planning process still creates a static dose distribution delivering the prescription dose but
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to a larger target volume than CTV. It cannot predict or estimate the difference between
the planned and the delivered dose distributions.

Figure 11: one dimensional continuous Gaussian filter

To retain the spatial information, a Dose Convolution Filter (DCF) is used. DCF
was initially developed by Y. Huang et al to incorporate spatial dose information into
tissue modeling.34, 45 Tissue response was calculated by the relative-seriality NTCP model
with DCF-filtered dose distribution as input.
published data.

The parameter σ was determined from

After applying the DCF, the NTCP model successfully fitted the

experimental data with a predicted value of σ  2.6  0.5mm , which is consistent with
2mm migration distances of remyelinating cells.

This proves that outcome can be

predicted more accurately using DCF-filtered dose distribution than that from static dose
distribution.34 A similar concept has been reported independently by M. Adamus-Gorka et
al. by assuming an effective size of functional sub-units.72 In its original format, DCF was
a one dimensional Gaussian filter (Figure 11) which was applied to the beam profile along
the spinal cord. We have applied the DCF concept here and in addition to its originally
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proposed use to predict the effects of cell migration and bystander effects, DCF is applied
to also simulate the effect of random setup uncertainties and organ movements.73
Furthermore, DCF is expanded to three dimensions. The degree of smoothing in each
dimension can be defined independently to help simulate real situations. DCF may help
provide a more accurate prediction of tumor control and tissue response by incorporating
the fact that individual volume elements do not exist at the same location within the dose
distribution at every fraction and that cells may migrate from one volume element to
another.
In this work, two types of three dimensional DCF are provided: isotropic DCF and
anisotropic DCF.

In isotropic DCF, the three dimensions have the same degree of

smoothing. In anisotropic DCF, the three dimensions can be controlled independently.
The size of DCF is defined by the number of voxels. Voxel size is obtained from DICOM
RT files exported from Eclipse. For example, a two dimensional filter of size 3x3 is shown
in Figure 12. The values in the filter matrix (discrete probability density) are determined
by the parameter σ in the Gaussian function. The edges of the original matrix are padded
with zeros for convolution purpose (Figure 12).
The degree of smoothing is defined by both the size of DCF and the parameter σ.
The size indicates how distant a voxel is affected by its surrounding voxels, while the σ
determines how a voxel is weighted inside a region of the filter size. As in Figure 12, the
filter with σ 2  0.5 is more center-weighted than the filter with σ 2  2 . One can imagine,
as σ gets bigger and bigger, the convolution result for each individual voxel approaches the
mean value of the convolving voxels. On the other hand, as σ gets smaller and smaller, the
convolution result for each individual voxel approaches its own value. Figure 13 shows an
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example of 2D smoothing. The original data is a 20x20 matrix with random values. The
data were convolved with filters of different sizes and different σ values from which we
can see the effect of the parameters. It is worth to point out that when σ value is small (e.g.

σ 2  0.5 ), the size of the filter has little impact on the degree of smoothing.
2

Size 3x3

2

σ = 0.5

σ =2

?

?

?

0.0113 0.0838 0.0113

0.1019 0.1154 0.1019

?

?

?

0.0838 0.6193 0.0838

0.1154 0.1308 0.1154

?

?

?

0.0113 0.0838 0.0113

0.1019 0.1154 0.1019

2

8x10 matrix convolves with 3x3 filter (σ = 2)
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19.51

16.86

57.46

0

0

52.91

38.69

23.08

43.81

35.66

35.91

31.85

6.34

26.41

14.44

0

0

40.15

22.58

34.98

20.63

1.35

28.26

39.27

36.66

31.63

40.57

0

0

11.43

11.46

15.11

35.04

25.52

41.76

24.46

46.73

27.45

17.34

0

0

22.14

25.70

17.43

6.47

18.76

41.99

49.20

25.41

52.52

40.31

0

0

27.64

28.92

37.03

54.38

9.69

38.31

43.10

5.45

31.08

41.71

0

0

58.90

7.24

15.92

52.78

10.73

2.02

58.12

15.99

56.62

4.08

0

0

0

0

0

0

0

0

0

0

0

0

0

Figure 12: An 8x10 matrix convolves with 2D 3x3 Gaussian filters
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a) Original

2

b) Filtered, 3x3, σ = 0.5

2

d) Filtered, 3x3, σ = 2

Figure 13: Effect of the filter parameters (size and σ).

2

c) Filtered, 5x5, σ = 0.5

2

e) Filtered, 5x5, σ = 2
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2.1.2 Spatial DVH

Figure 14: The sDVH concept and a typical result.
To restore the spatial information to DVH format, we divide the target volume into
sub-volumes and assign one color to each sub-volume. So the colors represent the spatial
locations. Then we color-code the spatial information on the original DVH. The division
of the target volume is computerized and can be made based on the known clonogen
density distribution or the metabolic or biochemical activity distribution provided by
functional imaging such as PET-CT (Positron Emission Tomography – Computed
Tomography) images. For the examples presented in this work, we arbitrarily choose three
regions for illustration purpose: center, middle, and periphery (Figure 14, additional
regions can be defined as desired). Dose voxels in the different regions are color-coded in
the cumulative or differential DVH (Figure 14). Thus a measure of spatial information is
restored to the DVH in a format we call the spatial dose-volume histogram (sDVH).
Statistics for "cold" spots, characteristics for differential sDVH peak (peak height, full-
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width at half maximum (FWHM) and full-width at tenth maximum (FWTM)), and
conformity information are also presented on the differential sDVH figure as they have
proven useful in quantifying relative plan quality.

2.2 Biological Modeling
2.2.1 Fractionation sensitivity

Figure 15: Isoeffects of different fractionation schemes for a variety of normal tissues
(Ref. 44).
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As mentioned in the first chapter, radiotherapy is commonly delivered in multiple
fractions with the exception of stereotactic radiosurgery in which the dose is delivered in
one fraction. Fractionation schemes may vary depending on the tumor site, the tumor stage,
and the institution‟s protocol, etc.

Design of a fractionation scheme involves an

understanding of dose response behavior of both the tumor and normal tissues and the total
prescription dose is dependent upon the fraction size. For example, a prescription dose of
70Gy delivered in 35 fractions is not biologically equivalent to the dose of 70Gy delivered
in 10 fractions, i.e. 2Gy/fraction x 35fractions ≠ 7Gy/fraction x 10fractions. This is
because different organs or tumors react to fractionation differently (Figure 15
radiobiology, this is usually termed the fractionation sensitivity.

74

). In

Optimization of a

fractionation scheme requires knowledge of the relationships between total dose and dose
per fraction for late-responding tissues, acutely responding tissues and tumors.44
Models have been developed to describe the fractionation sensitivity, among which
the linear-quadratic (LQ) model is the most popular (Figure 16). The LQ model is a
mathematical fit to the cell survival curves but also carries physical meanings. The linear
term α describes the lethal component of cell killing (DNA double strand breaks) induced
by radiation. And the quadratic term β describes the sub-lethal damages where cells can
repair (DNA single strand break). We chose to use the LQ model because it is widely
accepted, simple and elegant and carries good explanation to the underlying reactions.
Assuming there is fully repair between fractions, the cell survival fraction (SF) after
irradiation predicted by the LQ model is:
SF = exp
(−αD − βDd)
where α is the parameter for the linear component and β is the parameter for the quadratic
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term. D is the total prescription dose and d is the single fraction dose.

Figure 16: Linear-quadratic (LQ) model (Ref. 44).

On the other hand, in order to evaluate treatment plans created in different
fractionation schemes for the same patient, a conversion of effective dose from one scheme
to another is desired.

This conversion incorporates fractionation sensitivity which is

described by the α/β value. Based on the LQ model, the conversion can be expressed as:
Dref = D

d+α β
dref + α β
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where d is the physical fraction dose and D is the total dose. Dref is the total dose
normalized to a reference fraction scheme incorporating fractionation sensitivity. dref is the
reference dose per fraction used for the calculations. It is commonly chosen as 2Gy.
d+α β
EQD2 = D
2+α β
2.2.2 Low-dose HyperRadioSensitivity (HRS)
The LQ model works very well in most clinical cases. But when doses are below
1Gy, the LQ model may underestimate the effect of radiation due to the fact that tumor
cells may exhibit low-dose hyperradiosensitivity which is known as HRS.44 As shown in
Figure 17, the dotted line is fitted by the LQ model. But for doses less than 0.3Gy, the
cells exhibit much higher sensitivity than that predicted by the LQ model. A possible
reason is that at such low dose, the cell repair mechanism is not activated. As the dose
increases from 0.3 to 1Gy, cells have increased radioresistance (IRR) presumably due to
induced repair.44 So the overall cell killing below 1Gy is under-estimated by the LQ model.
A correction to the LQ model is needed for such low doses. In this work, we employed the
Induced Repair (IR) model 75-77:
SF = exp−αd 1 + αs α − 1 e−d

dc

− βd2

To convert the physical dose to EQD2, we include the HRS factor into the α/β.
d+ α β
EQD2 = D
2+ α β
and

HRS
HRS
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α

β

HRS

=

α
1 + αs α − 1 e−d
β

dc

where 𝛼𝑠 is the larger α at very low doses approaching zero; d is the single fraction dose;
𝑑𝑐 is the constant at which induction of repair is 63% complete.

Figure 17: HRS experimental data (asynchronous T98G human glioma cells) fitted with
LQ model and IR model (Ref. 76). The parameter αr is the same as the linear component
factor in the LQ model.
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2.2.3 Generalized Equivalent Uniform Dose (gEUD)
Dose distributions in radiotherapy are usually non-uniform, especially in IMRT. A
natural question is how much dose an entire structure will receive from a specific treatment
plan. In other words, what is the Equivalent Uniform Dose (EUD) to the structure? EUD
was introduced as the biological equivalent dose that, if delivered uniformly to the entire
structure, results in the same cell killing as the non-uniform dose distribution would. EUD
was initially defined for targets only.59 The concept was later expanded to include normal
tissues as well and is termed as generalized EUD (gEUD).60, 78 The equation is
1
gEUD =
N

1/a

N

dai
i=1

where di is the dose in voxel i; N is the total number of voxels; a is the volume parameter
which indicates the relevance of the non-uniformity of dose distributions. For targets, a<0.
For normal organs, a>0. As a approaches -∞, gEUD equals the minimum voxel dose
which means the low dose in the target dominates. Similarly, as a approaches +∞, gEUD
equals the maximum voxel dose which means the high dose in the normal organ dominates.
For example, in Figure 18 the average value of the table data is 3. If we set the a value to 5,
the gEUD would be 3.6. If the a value is 100 instead, the gEUD will becomes 4.9 which is
approaching the maximum value 5. When a = 1, gEUD becomes the arithmetic mean.
The gEUD often needs to be normalized to 2Gy fractions (gEUD2).79 This can be
done either before or after calculation of gEUD. We will discuss this in more detail in
section 2.3.
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Figure 18: The character of the parameter a in gEUD calculation.

2.2.4 Tumor Control Probability (TCP)
TCP is a very common term in the field and is used mostly by researchers to predict
the local control at a defined time. The shape of TCP curves follows the cumulative
function of the continuous normal distribution (Figure 19). In this work, we deployed both
logistic and Poisson TCP models.80-81
The logistic TCP model is a phenomenological model.80 The equation can be
expressed as:
TCP =

1
D50
1 + gEUD
2

1 4γ

where D50 is the dose at 2Gy/fraction that results in 50% of tumor control; γ is the slope
parameter of the TCP function at D50.
The Poisson TCP model is based on Poisson statistics and describes the probability
of no surviving clonogens.81 If we assume there are total N clonogenic cells and the
survival fraction (SF) of clonogenic cells of a given dose D is SFD, the Poisson TCP is
TCP = exp−N ∙ SFD
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Now let us apply the LQ model to include fractionation sensitivity. Recall that
SF = exp−αD − βDd
The Poisson TCP based on the LQ model becomes
TCP = exp −N ∙ exp −αD − βDd
A common parameter in using the Poisson TCP model is SF2 which is the
surviving fraction after a single 2Gy dose. If we convert physical dose to dose in 2Gy
fractions (i.e. EQD2 or gEUD2), the Poisson TCP model can be express in SF2 and EQD2
or gEUD2:
TCP = exp −N ∙ SF2gEUD 2

2

TCP = exp −N ∙ SF2EQD 2

2

or

The first form is used in SABER Model 1 and 2. The second form can be applied to
individual voxels, which forms the voxel-by-voxel Poisson TCP model assuming any
surviving clonogenic cell can repopulate the tumor:81
n

exp −Ni ∙ SF2EQD 2,i

TCP =

2

i=1

where Ni is the initial number of clonogen cells in voxel i; EQD2,i is the EQD2 in voxel i;
and n is the total number of voxels. If we assume uniform clonogen density, Ni=N/n.
2.2.5 Normal Tissue Complication Probability (NTCP)
Similar to TCP, NTCP is another frequently used term which describes the
complication rate of a normal organ at a specific end point. The NTCP curve also follows
the sigmoid shape like TCP (Figure 19). We adopted three NTCP models in this work.
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The first one is logistic NTCP model.80 It has the same form as the logistic TCP
and it is purely a phenomenological model.
NTCP =

1
D50
1 + gEUD
2

1 4γ

where D50 is the dose at 2Gy/fraction that causes 50% of complication; γ is the slope
parameter of the NTCP curve at D50.
The second one is the so-called LKB model and was named in honor of the three
authors – J.T. Lyman, G.J. Kutcher and C. Burman.57-58
NTCP =

2

x
t
−
2
e
2π −∞

1

dx,

where t =

gEUD 2 −D 50
m∙D 50

D50 is the dose at 2Gy/fraction that causes 50% of complication; m is the slope parameter
of the NTCP curve at D50.
The third model we included in the SABER software is the relative seriality NTCP
model.54 The model is derived based on the architecture of tissues (parallel, serial, and/or
cross-linked functional subunits). The equation is:
1
s

n

NTCP = 1 −

1 − P Di

s 1 n

i=1

D50
and P(Di ) = 1 +
gEUD2,i

4γ −1

where D50 is the dose that would cause 50% complication; 𝛾 is the slope of dose response
curve at D50; s is the fitted relative seriality parameter of the tissue; n is the total number of
voxels.
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2.2.6 Complication-free Tumor Control Probability (P+)
Complication-free tumor control probability or tumor control without normal tissue
complications (P+) is another term that combines TCP and NTCP and is commonly used to
predict treatment outcomes. It gives a single value that takes into account the predicted
tumor control and predicted normal tissue complications for a treatment plan. In general,
P+ can be calculated as:82
P+= TCP − TCP ∙ NTCP
= TCP − NTCP + δ ∙ 1 − TCP ∙ NTCP
where δ specifies the fraction of patients with statistically independent TCP and NTCP.
The approximate value of δ is 0.2.54, 82

Figure 19: Tumor control probability (TCP, green line), normal tissue complication
probability (NTCP, red line) and complication-free tumor control (P+, blue line).
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2.3 SABER models
We provide three models to predict TCP and NTCP. Let us begin with TCP.
Model 1:
Voxel dose di  structure gEUD  structure gEUD2  structure TCP
We start from voxel doses to calculate gEUD. Then convert it to gEUD2 which is
the gEUD normalized to 2Gy per fraction. Equations are:
gEUD2 = gEUD

gEUd + α/β
,
2 + α/β

where gEUd =

gEUD
# of fractions

TCP is calculated based on gEUD2.
In this model, the only parameter that can be varied spatially is the a value as the
3D dose matrix is converted to a single number (gEUD) in the first step. By nature, the
parameter a is the fitted value that makes the effect of a uniform dose distribution the same
as the effect of a non-uniform dose distribution. So theoretically the parameter a is a
constant for a specific region of interest.
Model 2:
Voxel dose di  voxel EQD2,i  structure gEUD2  structure TCP
We start from voxel doses and convert the physical dose matrix to EQD2 matrix.
The gEUD2 is directly derived from the EQD2 matrix. Then TCP is calculated from
gEUD2.
In this model, the EQD2 is converted from physical dose voxel by voxel. So the
fractionation sensitivity (α/β) could vary spatially. Currently a constant value is used for
each structure. As we obtain such information in the future, the variation could be easily
incorporated.
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Model 1 and Model 2 would yield different values of structure gEUD2 and thus
different TCPs. We will discuss this in detail in the later chapter.
Model 3:
Voxel di voxel EQD2,i  voxel TCPi  structure TCP
We also start from the actual voxel doses and convert the physical dose matrix to
EQD2 matrix. After that, TCP is calculated for each individual voxel (TCPi). The overall
TCP is then derived from TCPi.
The significant difference between Model 2 and Model 3 is that in Model 3 no
gEUD formulism is used. So we could vary not only the fractionation sensitivity (α/β), but
also the clonogen density and the radiosensitivity if such information is available.
Similarly, we provide three models for NTCP.
Model 1:
Voxel dose di  structure gEUD  structure gEUD2  structure NTCP
Model 2:
Voxel dose di  voxel EQD2,i  structure gEUD2  structure NTCP
Model 3:
Voxel di voxel EQD2,i  structure NTCP
In Model 1 and Model 2, both logistic NTCP model and LKB NTCP model are
available. In Model 3, NTCP is calculated using the relative seriality NTCP model.54

2.4 Work flow
Treatment plans are created in the Eclipse treatment planning system. DICOM RT
files (dose, structure set, and plan) are exported without CT images, thus anatomy
information is not used in the SABER software. For each treatment plan, three DICOM
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RT files (dose, structure set, and plan) are imported into the SABER software.
A 3D dose matrix is constructed from the DICOM RT dose file. In the DICOM RT
dose file, the dose values stored for each voxel are not actual doses in Gy or cGy, but very
large unsigned integers.

There is an attribute in the DICOM RT file called

“DoseGridScaling” which is the factor to convert the large integers to actual values in Gy
or cGy. In this work, the scaling factor is used when constructing the 3D dose matrix. The
3D physical dose is then converted to EQD2 using the LQ model.44 We also provide an
option to convert to EQD2 using the IR model which takes into account HRS.83-84 The
conversion from physical dose to EQD2 takes place at different steps depending on the
selected SABER model. Both the original 3D physical dose and the new 3D EQD2 are
retained and can be displayed by the software.
To approximate the effective delivered dose distribution from the static dose
distribution, we apply a 3D DCF to the 3D physical dose and the 3D EQD2 distributions.34,
73

In this software, we create two formats for the application of DCF: a) isotropic DCF in

which the degree of smoothing is the same for all directions; b) anisotropic DCF in which
the degree of smoothing can be different for all three dimensions. In both formats, the user
is able to define the degree of smoothing (the size of the filter and Gaussian σ). Both the
original and the DCF-filtered dose distributions are retained and can be displayed by the
software.
Structure contour points and coordinate information are gathered from the DICOM
RT files. The software categorizes target dose voxels by their locations within the PTV.
For the examples presented in this work, we arbitrarily choose three regions for
categorization: center, middle, and periphery (Figure 14, additional regions can be defined
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as desired). The periphery contains voxels within the most outer shell of the PTV. The
shell of voxels next to the periphery is defined here as middle, and the remainder of the
PTV is categorized as center. The thickness of the periphery and the middle can be
modified individually as desired. For the examples in this study, the thickness of each
region is chosen as one voxel dimension. Voxel size is determined by the Calculation Grid
Size and the Calculation Model settings within the Eclipse TPS. Dose voxels in the
different regions are color-coded in the cumulative or differential DVH (Figure 14). Thus
the sDVH is created.
From the 3D physical dose distribution, gEUD59 is calculated and normalized to
2Gy fractions. Similarly, from the 3D EQD2 distribution, gEUD279 is derived. To predict
treatment outcome, we develop a “Biological Evaluation” module which provides the three
SABER models using existing TCP models (Poisson79, 81, logistic80, and voxel-by-voxel
Poisson), NTCP models (logistic80, Lyman–Kutcher–Burman57-58, and voxel-by-voxel
relative seriality54) and P+54.

A simplified function called “Excel BioEval” is also

provided for simple and quick biological plan evaluation.

The function generates a

programmed Excel workbook in a few seconds which includes gEUD, TCP, and NTCP for
all structures.

2.5 Research materials
Eclipse TPS v8.1 (Varian Medical Systems Inc., Palo Alto, CA).
Post-treatment anonymous CT images (in Eclipse TPS).
Exported DICOM RT files (dose, structure set, and plan only.
information).
Matlab v7.9 (The Mathworks, Inc., Natick, MA).

No anatomy

42

CHAPTER 3
SABER Software Demonstration
3.1 SABER Software Demonstration
In this chapter, I will present the detailed features of the SABER software including
software screenshots and examples of using the software.

Figure 20: SABER software main graphical user interface. On the left are the function
panels. The four figures as shown are: top left isodose lines; top right, iso-EQD2 lines;
bottom left: cumulative DVHs; bottom right: cumulative eqDVH (DVH normalized to 2Gy
fractions). The dotted lines represent the DCF-fitted DVHs. The vertical dashed line is the
prescription dose (on DVH figure) or prescription dose normalized to 2Gy fractions (on
eqDVH figure).
Figure 20 is a screenshot of the main graphical user interface of the SABER
software. The four figure windows have black background which is similar to Eclipse TPS
and is more comfortable to look at on a computer screen. White background is also
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available which is more suitable for printouts (Figure 25). On the left side are the function
panels. Users can choose a tumor site and load plans exported in DICOM RT format or
Matlab format previously saved using this software (Currently only a few tumor sites are
included in the selection. The selection is used to read the parameters values stored in the
build-in library. If the tumor site studied is not included in the list, user is still able to use
the SABER software. But in such cases, the user has to provide all the parameters).
Functions provided here are:
1) view doses in percentages or absolute values (Gy) (Figure 20 vs Figure 22);
2) display isodose and iso-EQD2 lines or color wash map (Figure 20 vs Figure 21);
3) turn DCF on or off;
4) change structures‟ α/β values (Figure 23);
5) select isodose levels to display on isodose and iso-EQD2 plots (Figure 24);
6) plot cumulative DVH for selected structures (Figure 20);
7) plot differential DVH for selected structures (Figure 21);
8) plot sDVH (both differential and cumulative) (Figure 26, Figure 27);
9) execute “Excel BioEval” which performs simple and quick biological evaluation
and returns the output in Excel format (Figure 28).
Additional functions can be found in the “Tools” and “Options” menu at the top of
the main graphical user interface. Additional functions include:
1) execute “Biological Evaluation” module (Figure 29);
2) execute “Bio Plan Comparison” module (Figure 36);
3) use the IR model for EQD2 conversion instead of the LQ model (Figure 30);
4) measure dose profile from color wash dose map (Figure 31);
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5) switch between isotropic DCF and anisotropic DCF and modify DCF parameters
(size of filter and σ of Gaussian) (Figure 32). Reloading of DICOM RT files is required
for this function to take effect.

Figure 21: SABER main graphical user interface. Colorwash dose map and differential
DVH are displayed.
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Figure 22: SABER main graphical user interface. Isodose lines in absolute values.

Figure 23: Window for changing α/β values.
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Figure 24: Select/change isodose levels to display
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Figure 25: SABER main graphical user interface.
background which is more suitable for printouts.

The four figures are on white
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SABER not only plots physical DVH and eqDVH (DVH normalized to 2Gy
fractions), but also plots DVH and eqDVH from DCF-filtered dose distributions on the
same figure. The dotted lines represent DCF-filtered DVHs, which we can compare with
the original DVH to see the effect of the DCF application.
The SABER software provides sDVH in both cumulative and differential formats.
A typical output from the sDVH module is shown in Figure 26. On sDVH plots, the
numeric fraction volume of cold spots of each defined spatial location is also shown in the
legend area. Each bin height in the differential sDVH figure is the absolute number of
voxels at that dose level. The total colored area is the target volume. The cumulative
format, on the other hand, has two parts separated by the prescription dose. On the left
side are the under-dosed volumes; while on the right side are volumes that receive doses
equal to or higher than the prescription dose. The color bars on the left side of the
prescription dose are the cumulative summation of under-dosed voxel volumes from the
lower end. In Figure 26, the sDVH results are from the original static physical dose
distributions. We could also generate sDVH from EQD2 dose distributions (if it proves to
be useful) or DCF-filtered distributions (Figure 27).
The “Excel BioEval” function, which only takes a few seconds to generate a
programmed Excel workbook, is for simple and quick biological evaluation. As shown in
Figure 28, all structures are included in the Excel file with one structure on each worksheet.
Original DVH data are extracted from the DICOM RT dose file (DICOM attribute
“DVHSequence”). All cells are filled and programmed automatically by the SABER
software and it is extremely convenient for users to change the parameter values and
immediately see the corresponding results.
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The “Biological Evaluation” module (Figure 29) within the SABER software
performs more comprehensive biological evaluation based on the three SABER models.
This module supports the three NTCP models and three TCP models. The first two models
of each group are based on gEUD2 and the third one is voxel-based. Parameter values are
filled automatically if the SABER software finds a match in its built-in library. The user is
free to modify any parameter including whether to apply the DCF (a simple click on the
checkbox to turn on or off). To assist in justifying the prescribed dose, a figure with TCP
curve, NTCP curve, and P+ curve as a function of prescription dose is provided (Figure 29).
Though there are high uncertainties associated with the biological parameters and the
numeric values should not be considered as absolute, the relative magnitudes of these
values are valuable for plan comparison purposes. Hence the “Bio Plan Comparison”
module is provided to compare plans to a base plan (Figure 36). For the same reason, we
also present multi-variable TCP, NTCP, and P+ figures as functions of their own
parameters to cover large possible ranges for these values (Figure 33, Figure 34, Figure 35)
79

.
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Figure 26: Typical sDVH. Top: differential sDVH; bottom: cumulative sDVH.
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Figure 27: Typical sDVH. Top: differential sDVH; bottom: cumulative sDVH.
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Figure 28: Excel BioEval function demonstration. The Excel workbook is created in
several second by the SABER software. All equations are programmed by SABER. For
example, the α/β value for spinal cord was changed from 5 to 3. All results were instantly
updated.
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Figure 29: SABER's "Biological Evaluation" module. The screenshots shown here are
just three examples of different combinations of existing TCP and NTCP models.
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Figure 30:Parameter input window for low dose hypersensitivity (HRS) using the IR
model, which replaces the LQ model for converting physical dose to EQD2.
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Figure 31: Example of using the dose profile function. The profile can be measured from a
physical dose colorwash figure or an EQD2 colorwash figure.
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Figure 32: Window for changing DCF preference – isotropic DCF or anisotropic DCF.
User is able to define/change filter size and σ value.
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A

B
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D

Figure 33: Multi-variable TCP figures. Color scale represents TCP values. A) Logistic
TCP as a function of D50 and α/β for a 2Gy/fraction treatment. TCP values do not change
with respect to α/β values. B) Logistic TCP as a function of D50 and α/β for a hypofractionated treatment (>2Gy/fraction). C) Poisson TCP as a function of SF2 and α/β for
the same treatment as in B. D) Voxel-by-voxel Poisson TCP as a function of SF2 and α/β
for the same treatment as in B.
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Figure 34: Multi-variable NTCP figures. Color scale represents NTCP values. A) Logistic
NTCP as a function of D50 and α/β. B) LKB NTCP as a function of D50 and n. C) LKB
NTCP as a function of D50 and α/β. D) relative seriality NTCP as a function of D50 and s.
E) relative seriality NTCP as a function of D50 and α/β. All figures are generated from one
hypo-fractionated prostate treatment plan.

59

A

B

C

D

E

F

Figure 35: Multi-variable P+ figures. Color scale represents P+ values. As shown are
examples of P+ as a result of A) Logistic NTCP (α/β) and logistic TCP (α/β); B) Logistic
NTCP (α/β) and Poisson TCP (α/β); C) LKB NTCP (n) and logistic TCP (α/β); D) LKB
NTCP (n) and Poisson TCP (α/β); E) relative seriality NTCP (α/β) and voxel-by-voxel
Poisson TCP (α/β); F) relative seriality NTCP (s) and voxel-by-voxel Poisson TCP (α/β).
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Figure 36: "Bio Plan Comparion" module. By default, only SABER Model 3 is selected
for simplicity. Absolute NTCP, TCP and P+ values for the base plan are provided at the
bottom.
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CHAPTER 4
Discussion and Conclusions
In Model 1, gEUD is calculated first and then the LQ model is applied to normalize
the gEUD to 2Gy fractions which becomes gEUD2. While in Model 2, the order is
switched. We first apply the LQ model to convert physical voxel doses to 2Gy fractions
and then calculate gEUD which is actually the gEUD2 because all voxel doses have been
normalized to 2Gy fractions. The change of the order would result in different results of
gEUD2. To illustrate that, let us look at a simple mock example. Suppose half an organ
receives 60 Gy and the other half receives 30 Gy in a 30 fraction course of treatment.
Assume α/β = 3 Gy and a = 2. By using Model 1, gEUD can be calculated:
1
gEUD = (602 + 302 )
2

1/2

= 47.43Gy

Normalize it to 2Gy fractions:
gEUD2 = 47.43

47.43 30 + 3
= 43.46Gy
2+3

Now if we apply the Model 2, the physical voxel doses are converted to 2Gy
fractions first. So the half of organ that receives 60Gy remains 60Gy, but the other half of
the organ that receives 30Gy becomes 30

30 30 +3
2+3

= 24Gy. Then we can derive gEUD2

from the EQD2 values:
1
gEUD2 = (602 + 242 )
2

1/2

= 45.69Gy

In the above example, the gEUD2 results have over 2Gy difference between the two
models. One can then apply NTCP models to calculate complication probability. For
example using the LKB model and assuming D50 is 60Gy and m is 0.25, we can get
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NTCPModel

NTCPModel

1

1
=
2π

2

1
=
2π

43.46−60
2
0.25×60 −x
e 2 dx

= 13.5%

−∞
45.69−60
2
0.25×60 −x
2
e dx

= 17.0%

−∞

We can do a similar mock example for target volumes. Suppose the target has
1000 voxels and 950 voxels receive 70Gy in a 35 fraction course of treatment and the rest
of the target receives 50Gy. Assuming α/β = 10Gy and a = -10, the gEUD2 calculated
from Model 1 and Model 2 would be 63.3Gy and 62.1Gy, respectively. The results can
then translate into different TCPs.
Depending on the nature of the spatial dose distribution, the relative effect of the
DCF will vary. For cases in which dose distributions are homogeneous DCF may have
only minor effects or may even be negligible, while for cases in which dose distributions
are very inhomogeneous the effect of DCF may be significant. Moreover, the effect and its
direction (whether it increases or decreases gEUD and thus TCP or NTCP), depends on the
volume, the dose level, and the spatial distributions of cold/hot spots (Figure 37 and Figure
38). Plans that have similar DVHs may respond to the application of DCF differently
(Figure 38), thus resulting in substantially different predictions for TCP and NTCP and
associated changes in relative plan ranking.
The sDVH is a simple and intuitive way to restore spatial information back into the
DVH format. From the sDVH, we can immediately see the distributions of under-dosed
voxels across chosen regions and whether and how many of such voxels exist in regions
where gross disease has been identified or is more likely to reside. For the example shown
in Figure 26 and Figure 27, the three regions are arbitrarily selected for illustrative
purposes. If, for example, we have clinical bases for assuming that the center region of a
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tumor is likely to have higher malignant cell density than the periphery, use of the sDVH
will enable us to easily select a plan with a preferable spatial dose distribution. In cases
such as Bijl‟s split-field irradiation45 on the rat cervical spinal cord where same total
length of cord was irradiated but with different spacings between the split fields, the sDVH
alone cannot differentiate between different plans. However, the application of the DCF
concept prior to calculation of the sDVH will allow differentiation.34
In addition to its application for plan evaluation purposes, the sDVH also has
potential applications for plan optimization. Figure 39 shows two plans with virtually
identical target and OAR DVHs. Significant differences in either target or OAR DVHs
would make the clinical decision relatively straightforward however, in the absence of such
differences, an investigation of the spatial distribution of the calculated absorbed dose is
warranted. For the example in Figure 39, Plan 3 is an IMRT plan optimized using regular
dose volume constraints. Plan 4 is then further optimized manually using the sDVH
concept. From sDVH results (Figure 40), we readily observe differences in the number of
under-dosed voxels in critical regions (under-dosed fraction in center region: 5% in Plan 3
versus 0.05% in Plan 4) and can choose the plan that is more favorable with respect to the
spatial dose distribution.

DVH-based optimization lacks objectives that regulate the

location of under-dosed voxels in the target. However, optimization incorporating sDVH
has the capability of reorganizing an inhomogeneous dose distribution in an attempt to
improve the spatial dose distribution. One might question whether such changes are
clinically relevant. This question is not easily answered and is similar to many of the
current questions regarding actual realized clinical advantages from any IMRT
optimization techniques. However, even if only a relatively small difference is observed,
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we would like to push the plan in an apparently favorable direction – this is the process of
"optimization". Application of sDVH requires only the target contours which are already
available in the current optimization algorithm in the Eclipse TPS, and the creation of the
different regions can be easily automated in most cases.
In the workbook created by the “Excel BioEval” function, all structures have both
TCP and NTCP programmed. When looking at one specific structure, the user would then
ignore either TCP or NTCP depending on whether the structure is an OAR or target.
While we could require the user to specify the structure type so that only TCP or NTCP is
generated, we prefer not to require any input from the user since the original motivation for
this function is to provide simple and quick results. For the same reason, we choose the
Excel format because it is accessible, programmable and universally available.
The more comprehensive “Biological Evaluation” module provides additional
options. The user can choose any of the different models from the drop-down lists. The
DCF can be turned on or off with a simple mouse click, making it extremely useful for
visually evaluating the effect of DCF application. The voxel-by-voxel TCP model makes
it feasible to incorporate spatial variations of clonogen densities (n), radiosensitivities
(SF2), and fractionation sensitivities (α/β) when those data are available. SABER is
capable of retaining the spatial variations as the dose information is processed at the voxel
level rather than using dose information that has been distilled into simpler forms. This
framework provides the potential to improve our understanding and prediction of the
effects of radiation dose distributions with the biological information we have now but will
also allow even further improvement if additional biological information such as clonogen
density, hypoxia, and spatial variations in biological parameters become known.
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The multi-variable TCP, NTCP, or P+ figure covers large parameter ranges and
provides information on how sensitive the probability is to the assumed parameters. A
wealth of biological data describing the effects of radiation on normal tissues has recently
become available in the form of the QUANTEC report (QUantitative Analyses of Normal
Tissue Effects in the Clinic) and this data is being incorporated into the software‟s build-in
library to provide more clinically relevant results.85 In Figure 35, only six P+ figures are
presented. In fact, SABER can provide such P+ figures as a result of any TCP (Figure 33)
and NTCP (Figure 34) combination.
In spite of that there are large uncertainties associated with the biological
parameters in TCP, NTCP and P+ predictions, the relative magnitudes are valuable for
plan comparison purposes. The “Bio Plan Comparison” module provides capabilities to
analyze and compare multiple treatment plans for the same patient (Figure 36). The
module integrates all three SABER models and deploys all existing TCP/NTCP/P+ models
as presented in the “Biological Evaluation” module. For simplicity, only the voxel-byvoxel Model 3 is selected by default (Figure 36). Users are free to select any or any
combination of the three SABER models for plan comparison. For example in Figure 36,
all three models are selected. The voxel-by-voxel Model 3 tends to predict a lower TCP
which is expected assuming individual voxel TCPs are multiplicative.

This is in

comparison to gEUD methods which calculate TCP over multiple voxels.
An important result in the example of Figure 41 is that the plan rankings changed
from Model 1 to Model 2 or 3 if we sort plans based on the NTCPs of the rectum. Based
on SABER Model 1 (voxel dose  structure gEUD  structure gEUD2  NTCP), the
UWHypo plan yields the least NTCP. However, if one sorts the plans using either Model 2
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(voxel dose  voxel EQD2  structure gEUD2  NTCP) or Model 3 (voxel dose 
voxel EQD2  NTCP), the plan rankings are altered. The Plan 2 turns to yield the least
NTCP and UWHypo becomes the worst. Although the NTCP differences between the
plans are relatively small in this example (<2%), it proves that the choice of biological
models can change the biological results. If we compare the results from the top figure
(without DCF) with the bottom one (with DCF) in Figure 41, we found another important
result, which confirms our discussion about the effect of DCF in the beginning of this
section. The DCF does alter the plan ranking in this example. So the effect of cell
migration, setup uncertainty, inter- and intra-fraction motions should be carefully
examined and be taken into account when making clinical decisions based on predictors
such as gEUD, TCP, NTCP and P+. The biological plan evaluation is much more complex
than evaluations based solely on physical dose. And one should be cautious when making
clinical decisions based on one radiobiological model.
We have developed a software tool named SABER which provides the treatment
planner with significantly more information to evaluate radiotherapy plans. The DCF
concept can be used to simulate the effect of random or systematic motions and thus
integrate such effects into the evaluation.

The sDVH concept incorporates spatial

information back into the DVH format. Multiple biological functions and models are
provided to facilitate greater understanding of the effects of planned and delivered dose
distributions as well as the ability to better predict outcome. SABER incorporates both
spatial and biological information into plan evaluation and provides a framework for
incorporating additional biological information into the plan comparison and optimization
process when this information is available. This may significantly alter the predicted
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outcome and thus the choice of treatment plan. Thus SABER can help create more
optimum radiotherapy treatment plans and more accurately predict treatment outcome.
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Figure 37: Illustration of DCF effect on different static dose distributions. The dotted
white boxes are the target contours. Inside the contour, dose is 100% except the underdosed regions. Outside, dose is 50%. The σ is chosen as one pixel. (a) Volume effect: cold
spots have same level of dose but different volume (b) Dose level effect: cold spots have
same volume but different level of dose. DCF could lower a target‟s gEUD if the dose
falls sharply at the edges of the target.

69

Original distribution

Filtered distribution

decrease

increase

Original
Filtered 1
Filtered 2

Figure 38: Illustration of DCF effect on static dose. Top: on the left are static doses with
the same DVH but different spatial dose distribution; on the right are DCF filtered dose
distributions. Bottom: DVHs of the original dose distribution and the filtered dose
distributions.
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Figure 39: Two treatment plans from a prostate case. Top: DVHs. Two treatment plans
have virtually identical target DVHs and very close OAR DVHs. Bottom: Dose
distribution comparison.
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Plan 3 sDVH

Plan 4 sDVH

Figure 40: The sDVH for the two prostate treatment plans (Figure 39). Top: differential
sDVH and cumulative sDVH for Plan 3. Bottom: differential sDVH and cumulative
sDVH for Plan 4.
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Figure 41: “Bio Plan Comparison module”: Top: DCF is OFF; bottom: DCF is ON. All
three SABER models are selected. Base values in each SABER model are the absolute
NTCP/TCP/P+ values of the first plan, i.e. the “UWHypo” as in this example. In this
example, the plan rankings based on NTCP are different from the three models, and
application of DCF also alters the plan rankings.
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CHAPTER 5
Future Work - Technology versus Biology
As we discussed in the introduction, the physical aspects have been continuously
improved, which results in more and more complex radiotherapy treatment machines.
However, the discussion in the previous chapter suggests that the biological aspects are
needed in order to create better optimized treatment plans. To continue the discussion, I
start this new chapter of “Technology versus Biology” because the biological aspects are
so important and should not be overlooked.
Radiotherapy has traditionally participated in a steady march toward incorporating
more and more complex technology and treatment techniques in an attempt to improve
local control and hence survival. The pace of this march has increased dramatically over
the past decade. This steady progression is in the name of improving the quality of
radiotherapy treatment but the metrics used to characterize this improvement are not
always clearly defined. It is very common to assess the quality of a treatment by looking at
the dose distribution, the limited dose escalation in target and dose reduction in normal
tissue 3, 12, 86-89. However, improvement of these metrics does not necessarily translate into
better local control of tumors and patient survival

24, 90

. Furthermore, we know that with

increased complexity comes increased risk for error and often increased uncertainty in the
delivered dose distribution. Thus, even given clearly defined quantitative metrics, it is not
always easy to define the circumstances under which increased complexity is justified for
the sake of improvements in radiotherapy plan quality.
The progression of treatment technologies from 3D conformal radiotherapy (3D CRT)
to static-field intensity-modulated radiotherapy (S-IMRT) to arc-based or rotational IMRT
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(R-IMRT) to proton therapy and other particle beam therapy has significantly widened our
options and improved our ability to shape the physical absorbed dose distribution

91-96

.

Better plan statistics generated within more powerful treatment planning systems are
generally assumed a priori to signify better plan quality. However, radiotherapy is more
than a pretty picture on a treatment planning system screen.

Overall treatment

effectiveness will be affected by a number of factors and while the quality of the dose
distribution is clearly an important metric, it is not the only relevant one. A number of
physical and biological factors are related to treatment outcome and changes in these
factors are often affected by the level of complexity of the treatment technique. The aim of
this paper is to discuss some of these factors which are not necessarily always considered
prior to employing highly complex technology for radiotherapy.

5.1 Dose distribution capability
The primary endpoint of much of the technology development in radiotherapy today is
the improvement of the physical absorbed dose distribution. Indeed, since the goal of
radiotherapy is to deliver full dose to the tumor and minimum dose to normal tissues, the
dose distribution is the most obvious indicator of treatment quality. The implementation of
inverse planning systems and S-IMRT delivery techniques has resulted in significant
reductions in absorbed dose to organs-at-risk (OARs) compared to 3D CRT

3-6

. Many

studies have been reported that, compared to 3D CRT, S-IMRT treatment leads to lower
normal tissue complication probability (NTCP)

7-10, 97

. This increased conformity can also

be exploited by escalating the dose to the target to achieve higher tumor control probability
(TCP) while maintaining OAR doses below their tolerance

11-13

. It should also be noted

that changes in the delivery technique can significantly change the absorbed dose
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throughout the patient, and not just in the vicinity of the target structure(s). For example,
in the study reported by Mansur et al

14

, the authors found that compared to 3D CRT, S-

IMRT treatment resulted in lower peripheral dose in regions closer to the target. However,
at distant points, S-IMRT deposited more dose than 3D CRT presumably due to S-IMRT‟s
higher monitor units and increased head leakage.
A more recent addition to IMRT technology is rotational IMRT or arc therapy (RIMRT) such as TomoTherapy (Tomotherapy, Inc., Madison, WI), RapidArc (Varian
Medical Systems, Palo Alto, CA), and VMAT (Elekta, Stockholm, Sweden). Many studies
have shown that R-IMRT can achieve a more conformal dose distribution and reduce
normal tissue “hot spots” compared to S-IMRT as well as delivering treatment faster
96, 98

92, 95-

. Generally speaking, R-IMRT treatment spreads the dose to normal tissues over a

larger volume than S-IMRT. However, theoretically the dose distribution achieved by RIMRT delivery should also be achievable by S-IMRT plans containing more fields at
different beam angles

99

. However whether it is better to dispose of the integral dose by

delivering a relatively lower dose over a larger volume than a relatively higher dose over a
smaller volume has not been proven clinically

100

. An animal study by Semenenko et al

suggests that for lung cancer treatment, R-IMRT may be at a disadvantage as it deposits
the dose to a larger volume 101.
Proton therapy and intensity modulated proton therapy (IMPT) have also been gaining
momentum, most notably in the United States. Because of the finite range of proton beams
and the delivery of increased dose within the Bragg peak, the absorbed dose distribution
can be made exceptionally conformal. Many studies have shown that the integral dose to
normal tissues can be significantly reduced without compromise to target coverage 89, 93, 102-
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. As a result of the highly conformal dose distributions and the absence of exit dose,

proton therapy could allow dose escalation to a new level but at a significantly increased
infrastructural complexity and financial outlay.
Better image guidance technology allows clinicians to potentially reduce PTV margins
which then provides increased latitude within which to capitalize on the more conformal
dose distributions offered by more sophisticated delivery techniques. However, as we
mentioned in the first chapter, reduced margins result in the potential hazard of a
geographical miss and the ionizing radiation from image guidance could make the
radiotherapy biologically less effective.24-25, 27, 105

5.2 Delivery mechanism
A variety of techniques are used to deliver IMRT treatments. For most of these
procedures, the treatment time ranges from 3 to 15 min. However, variations in machine
type, delivery method, plan complexity, and fraction size can increase delivery time to up
to 20–40 min. Use of stereotactic technique and respiratory gating can increase this time
even further

106-107

. The increase in treatment delivery time could affect the therapeutic

balance between the desired effect on the target volume and the unwanted normal-tissue
toxicity 105, 108-114.
Modeling studies suggests that a significant loss of biological effectiveness could be
expected if the fraction delivery time is longer than 15–30 min

108-109

. This has been

confirmed by experimental studies which show that the protraction of dose accumulation
over a longer duration reduces cell kill due to the repair of DNA damage

105, 113-114

.

Compared to a conventional 2-6 min treatment, the in vitro study confirms an increased
cell survival when the cells are irradiated with an IMRT protocol that is delivered in 20
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min.115 Moreover, the temporal pattern also affects the cell survival.105, 112 The in vitro
experiments reported by Yang et al results suggest that the survival fraction appears to
vary with the temporal pattern of dose delivery. 105 The modeling study by Altman et al 112
showed that it is biologically superior to deliver the dose in a “triangular” shaped temporal
pattern than in a “v-shaped” pattern presumably due to the fact that the “triangular” pattern
delivers a larger portion of the dose to the volume element over a shorter period of time. In
the work by Shaikh et al

116

, the delivery time to individual volume elements of the target

was analyzed for different types of IMRT delivery techniques.

This study predicted

greater than 5% biologically effective dose loss for 8–10 minute delivery times in the worst
case scenario. For treatment delivered in less than 2 minutes, the biological effective dose
(BED) loss is insignificant (<1%). So although S-IMRT has dose distribution advantages
over 3D CRT, the longer time to deliver dose to a volume element associated with S-IMRT
delivery results in a loss of biologically effective dose (BED) compared to 3D CRT.
Both modeling and experimental studies agree that the delivery mechanism has an
impact on BED. Longer delivery times can result in a loss of BED. Although such BED
loss could be compensated theoretically, it would be limited by large uncertainties
associated with the biological parameters necessary to calculate such compensation. And
because late-reacting normal tissues usually repair DNA damage more slowly than tumor
cells, a simple increase in dose would likely lead to worse late complications in order to
maintain tumor effectiveness in protracted delivery

111

. Thus it is ideal to deliver dose as

rapidly as possible.

5.3 Reliability of Technology
Another important factor influenced by the level of complexity of radiotherapy
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equipment is reliability. Conventional wisdom would suggest that the more complex the
piece of equipment, the more likely it is that one component or process of that equipment
will fail and this wisdom is supported upon examination of internal downtime data for
complex equipment. Such “breakdowns” do not necessarily imply physical or mechanical
failure but could simply represent the failure to communicate the appropriate information
to other components within the appropriate time period. A myriad of interlocks are
generally necessary to provide a failsafe environment within which to operate extremely
complex equipment. The consequence of this is increased machine downtime resulting in
un-planned treatment gaps or extended treatment length assuming only one fraction is
delivered each day and no treatment during weekends. Thus for the same treatment course,
an extended time period will be needed to complete the treatment using less reliable
equipment and highly complex equipment is often less reliable. Prolongation of treatment
allows tumors to repopulate and may be related to significant differences in treatment
outcome. Numerous studies have been published and can be found in section 1.3 in
Chapter 1. These studies indicate that dose escalation would be needed to compensate for
the dose loss due to accelerated tumor cell proliferation. However, dose escalation would
also increase the dose to normal tissues which results in higher complication rates. Thus
the treatment schedule should not be extended and thus the importance of machine
reliability in treating tumors in all sites is evident.

5.4 Technology versus Biology
Although more complex technology can provide the ability to achieve more conformal
dose distributions, this potential benefit could be lost due to other factors related to this
complexity, such as prolongation of individual treatment fractions or prolongation of the
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entire course of radiotherapy

46, 116

. To put this in context, let us compare dose escalation

with dose lost from treatment prolongation. Let us assume that modality A is very reliable
with an uptime of ~99.9% and is used to deliver 70Gy treatment (35 x 2Gy). This
treatment course will be at least 47 days assuming one fraction per day and no treatment
during weekends. Suppose that competing modality B can increase the target dose to 74Gy
while maintaining the same OAR doses as modality A.

The treatment course using

modality B will be at least 51 days. However, suppose modality B is relatively unreliable
with an uptime of 95%. On average, this will add 2 days to the treatment course (overall
53 days). If we apply the result from Withers et al which states that in head and neck
cancers treated beyond 4 weeks the effect of cell proliferation is equivalent to a loss of
radiation dose of about 0.6Gy/day

46

, one can calculate the effective dose for both

modalities:
A: 70Gy – (47–28) days x 0.6Gy/day = 58.6Gy
B: 74Gy – (53–28) days x 0.6Gy/day = 59.0Gy
So the difference between the effective dose delivered by these two modalities is not
significant (0.4Gy). The potential benefit of dose escalation using modality B resulting
from its superior dose distribution conformity is substantially lost due to its relative
unreliability and the additional cost of making modality B available is wasted. If modality
B also requires a longer time to deliver each dose fraction to a given volume element of the
target, there would be additional biological loss. For example, let us assume that modality
B causes only an additional 1% BED loss (0.74Gy) than modality A, a very conservative
assumption given existing predictions in the literature

108-109, 116

. Now the target BED

resulting from modality A is actually higher than that from modality B. The biological
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effects related to the complexity of the technology could therefore totally offset or even
reverse the dose escalation gain from using technologies with better dose distribution
conformity. The take home message is that radiotherapy is more than a pretty picture on a
TPS screen. A nice looking dose distribution on the static set of CT simulation images
does not alone predict a better outcome.
The example above illustrates the importance of other radiotherapy delivery factors
besides the dose distribution capabilities and one should not become singularly focused on
this parameter as the quintessential element in predicting outcome. It is also unfortunately
not uncommon for patients to miss scheduled treatments

117

. In addition, national holidays

during which the clinic is not open often arise during the treatment course. Taken together,
these issues could extend the treatment course by over one week. Significant losses in
effective dose can occur in such situations which raises serious concerns about the
predicted treatment outcome. The issue of machine reliability has quietly become a larger
factor over the years as equipment has gradually increased in complexity and could
potentially threaten to numb the radiation oncologist into accepting that missed treatments
are an unavoidable consequence of the complex technology required for high quality
radiotherapy. However, such highly complex procedures were not developed with the
intention that they would be administered to all patients regardless of disease, and
furthermore, the decision to allow a patient to miss a treatment due to equipment failure
should not be made lightly.
In order to achieve better dose distribution conformity using IMRT, the fluence map of
each field has to be more complex for a limited set of beam angles. Thus the degree of
complexity is usually increased. This may include more monitor units, smaller segment
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sizes, more segments, and more complex segment shapes. Studies have reported a tradeoff
between complexity and treatment quality as well as delivery accuracy

118-121

. Highly

complex plans typically result in greater uncertainty in both the dose calculation accuracy
and the delivery accuracy and thus clinicians are often required to make a decision as to
whether they will choose the plan that looks better on paper but carries greater uncertainty
in terms of what is actually delivered to the patient.
Furthermore, increased complexity is generally associated with greater risk for error.
Several of the radiotherapy errors recently publicized in the media are evidence of the
potential dangers of increased complexity in radiotherapy procedures.

Moreover, the

results of the head and neck phantom credentialing test from the Radiological Physics
Center are clear evidence of the increased probability for error when employing complex
technology

122

. The recent trend in radiotherapy of a rapid adoption of sophisticated

technology is certainly in part driven by factors other than the evidence-based
improvement in outcome, for example, the desire of facilities to keep up with their
competitors in terms of technological capabilities. Unfortunately, this trend seems to
emphasize technology over human resources

123

. There has been a major push in the field

of radiation oncology physics to assure appropriate training of those entering the practice
of clinical radiation oncology physics, however, we are at the same time rapidly expanding
the complexity of the landscape that these personnel practice in. It is estimated that more
people die each year as a result of medical errors than from breast cancer

124

, and

complexity is generally a key contributor to failures in the human-machine interface

125

.

Therefore, complexity should be minimized wherever possible and highly complex
techniques should be used only where there could be expected to be a distinct advantage

82

that outweighs potential negative consequences and complex treatments are not intended to
be administered to every patient.
In summary, advanced technologies can produce very conformal radiotherapy
treatment plans and allow more accurate target localization and more rapid dose delivery.
As a result, normal tissues can be better spared to reduce complications and the target dose
can be escalated to achieve higher control rates. While such clinical advantages are widely
publicized, we must consider other factors associated with increased complexity that could
influence the treatment effectiveness and patient safety.

The overall treatment

effectiveness depends on not only the dose distribution capabilities offered by the
technology but also on other key factors including the fraction delivery time, machine
reliability, delivery accuracy, and additional imaging dose administered before or during
treatment. The potential effects of these factors are discussed here but there may be other
biological factors associated with increased complexity as well. Furthermore, the cost of
complex technology can potentially hinder the facility‟s capacity to invest in the personnel
to effectively and safely utilize this technology. When considering the application of
highly complex technology, one needs to consider more than just the specification sheet.

5.5 Future Work
The SABER software incorporates biological and spatial information that are not
available in commercial systems. However, just like the technological development, the
biological evaluation and optimization also have a long way to go. For the immediate
future, I would like to investigate the following components.
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5.5.1 LQ-L; LQC

Figure 42: Experimental data showing that the LQ model over-estimates the cell survival
at higher doses (Ref. 127).

The LQ model works well in most clinical cases and at low doses we may apply the
IR model to include the effect of HRS.

As fraction doses become very large

(hypofractionation), the LQ model is also unable to predict the cell survival accurately
(Figure 42). At such large fraction doses, the response becomes more linear while the
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prediction based on the LQ model continues bending down which over-estimates the cell
killing. In such cases, we can apply the linear-quadratic-linear (LQ-L) or linear-quadraticcubic (LQC) model (Figure 43) to convert physical dose to EQD2.44, 126

Figure 43: Linear-quadratic (LQ) versus linear-quadratic-cubic (LQC) model (Ref. 44).

It should be relatively straight forward to incorporate the LQ-L or the LQC model.
For the LQ-L model, we need one threshold dose at which the survival curve becomes
linear. For the LQC model, we just need to replace the linear-quadratic equation with the
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linear-quadratic-cubic equation.
5.5.2 Time parameter

A radiotherapy treatment usually takes weeks. As we discussed in Chapter 1,
tumor cells can re-populate during the treatment and thus the effective dose becomes less
than the prescription dose. We can add the overall treatment time factor into the outcome
predictions.127
n

TCP = exp −

N0,i SFi
1

nf

exp −αdij − βd2ij ∙ exp

and SFi =
j=1

ln2
Td,ij

∆T

where N0,i is the initial number of cells in compartment i before the delivery of the first
treatment fraction; dij is the prescribed fraction dose to voxel i at fraction j, and nf is the
number of fractions; Td,ij is the potential doubling time of the cells in voxel i at fraction j
and ΔT is the average time between fractions. ΔT is equal to T/nf, where T is the overall
treatment time.
We can implement this time parameter into the SABER software in the Poisson
model. For simplicity in the first step, we can assume that the potential doubling time of
the cells is constant over all voxels during the entire treatment, i.e. Td,ij is constant. So the
surviving fraction of cells in voxel i becomes:
nf

exp −αdi − βd2i ∙ exp

SFi =
j=1

ln2
∆T
Td

Compared to the Poisson model presented in Chapter 2, here we only have an extra
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constant exp

ln 2
∆T
Td

, which is the overall treatment time factor. Thus the time parameter can be

incorporated into the SABER software.
5.5.3 Validation of Models with Clinical Data

Many models are used in this work including DCF, gEUD (and gEUD2), TCP,
NTCP, P+, and finally the three SABER models. While some models have been applied to
clinical data or at least a subset of clinical data, many remain to be validated. Because of
the large uncertainties associated with the parameters used in these models, the validation
will not be an easy task. It is possible that no model is absolutely right, but we would like
to know which model gives a closer match to the real world data.
The DCF has proved to be useful in predicting the dose wash-out effect for small
non-uniform field irradiation presumably due to cell migration.34 We have applied the
DCF in this work to simulate the dose wash-out effect due to various types of motion. The
parameter σ could depend on the specific treatment technique, for example, IMRT,
Stereotactic Body Radiotherapy or Stereotactic Radiosurgery. To predict the σ value, we
need not only the response data (e.g. TCP versus prescription dose), but also the planned
dose distribution (e.g. DICOM RT files). Then we can use the method described in the
DCF article34 to estimate σ.
A distinguishing feature in this work is that we provide three different methods (i.e.
the three SABER models) to predict the outcomes. As mentioned earlier, to validate which
model is the right one is difficult because of the large error bars associated with the
radiobiological models. However, we can fix the parameter values and compare which
model better predicts the clinical data. Again we need the clinical response data and the
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planned dose distribution in order to do this.
5.5.4 Spatial and Biological Optimization

The current work focuses on spatial and biological evaluation. We would like to
explore methods and/or algorithms to implement the spatial and biological metrics, such as
sDVH, DCF, and EQD2 or gEUD, into the optimization process.
EQD2 – Biological Optimization 1

EQD2 formula converts physical dose to biological dose by taking into account the
fractionation sensitivity. The SABER software can perform such conversion at the voxel
level. An intuitive way to biologically optimize the dose distribution is to replace the
DVHs in the current optimizer with the eqDVHs which is the equivalent DVH normalized
to 2Gy fractions. Currently, we can investigate this at the structure level. When the
biological information becomes available at the voxel level, we can easily adapt the
optimization to voxel basis.
gEUD – Biological Optimization 2

In the gEUD formula, the parameter a defines how relevant the level of
underdosing/overdosing is in a target/OAR. Thus gEUD could potentially be used to
reduce the under-dosed/over-dosed voxels in the target/OAR. For example, a possible
method is to limit the maximum dose allowed in a target and meanwhile optimize the dose
to achieve a minimum gEUD. Decreasing the a value (negative) will emphasize the
weighting of cold spots in calculating the gEUD and thus could reduce the level of
underdosing using the minimum gEUD.
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DCF – Spatial Optimization 1

DCF is a smoothing filter. As a result, small clots of cold spots could be smeared
out while big clots of cold spots could still exist after smoothing. Thus applying DCF prior
to gEUD optimization could potentially push the optimization toward the direction of
dispersed smaller clots of cold spots instead of big clots.
sDVH – Spatial Optimization 2

The sDVH is developed to evaluate the cold spot distributions across the defined
regions. In the discussion section in Chapter 4, I have demonstrated that it could be used to
further optimize dose distributions spatially, i.e. pushing the cold spots away from the
regions where we do not want cold spots. If the sDVH could be integrated into Eclipse, it
would be fairly easy to automate the additional optimization based on the sDVH concept.
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APPENDIX
Introduction to DICOM RT
In this work, DICOM RT files are used to transfer data from Eclipse TPS to
SABER software. DICOM stands for Digital Imaging and Communications in Medicine
and DICOM RT is the radiotherapy extension that has been added to DICOM standard
since 1997. It is difficult for one that has no DICOM experience to get started, which is
the situation I went through. Some information regarding processing DICOM files in
Matlab is presented here to help future researchers adapt more quickly to this environment.
Matlab has built-in commands to process DICOM files. The commands include
“dicomread”, „dicominfo” and “dicomwrite”. More information of these commands can be
found in the Matlab Help.

a) DICOM RT Dose
For a DICOM RT dose file, the head information can be read using the command
“dicominfo”. For example:
rdinfo = dicominfo(‘RD123456.dcm’);

% RD123456.dcm is the file of interest

The returned data “rdinfo” is a structure that contains many fields. One can double click
the variable “rdinfo” to see all the fields. To view a specific field, one can double click the
specific field in the Matlab “Variable Editor” window.

Alternatively, one can use

commands to read the fields. Here is an example to read the field “NumberOfFrames”:
TotalFrames=rdinfo. NumberOfFrames;
The answer returned is the total number of frames of the dose grid.
The command “dicominfo” only reads the headers. It won‟t read the actual dose
grid. To do that, one needs to use the command “dicomread”. For example:
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DoseGrid = dicomread(‘RD123456.dcm’)
The returned value in “DoseGrid” is 4D uint32 (unsigned 32-bit integer) data. But we
know that the actual dose values won‟t be all integers. If we look into the 4D uint32 data,
we will also notice that the dose values are very large. So the values must be scaled and
magnified. Now if we go back and look at the headers in “rdinfo”, we can find one field
called “DoseGridScaling”, which is the scaling factor that when multiplied by the dose grid
data, yields grid doses in the dose units as specified by the attribute “Dose Units”. The
“DoseGridScaling” is a very small number, typically at 10-5 or 10-6. A note here is that
before scaling the 4D uint32 data, one needs to convert the data from uint32 to double.
Otherwise, the scaled data would only have integers, such as 70, 71, 72, etc.

Figure 44: Architecture of DICOM RT dose grid.

Another question one would ask is why the dose is stored in 4D. The actual dose
should be just a 3D matrix. A closer inspection reveals that the third dimension is only 1
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value, i.e., the 4D data is l x m x 1 x n, where l is the number of rows and m is the numbers
of columns within one frame, and n is the number of frames along the axial direction
(Figure 44). The third dimension could be an indicator that specifies the type of the stored
matrix, i.e. grey value or true color, but I did not find any reference to confirm this.
Anyway, for this study it is irrelevant since it will not influence our results. To convert the
4D data to a 3D matrix, try the following commands:
rd3D=zeros(rdinfo.Rows, rdinfo.Columns, TotalFrames);
for i=1: TotalFrames
rd3D(:,:,i)=dicomread(‘RD123456.dcm’, 'frames', i);
end
A note here is that rdinfo.Rows and rdinfo.Columns specify the size of one frame. Now
the dose information has been stored in the variable “rd3D”, which makes it easy to
manipulate the dose grid.

b) DICOM RT Structure Set
Next let us take a look at the DICOM RT structure set. Suppose the file of interest
is RS123456.dcm. We can use the command “dicominfo” to read the file:
rsinfo = dicominfo(‘RS123456.dcm’);
Similar to the “rdinfo”, the returned value “rsinfo” is also a structure that contains many
fields. The contour information is stored under the field “ROIContourSequence” (Figure
45). There will be one item for each stored structure. For example, the first structure will
be “Item_1”, and the second will be “Item_2”, and so on. Open any of the items and you
will see the following three attributes:
-

ROIDisplayColor: the color of contours used in the planning system for the
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structure;
-

ContourSequence: the contour information of that structure;

-

ReferencedROINumber: used to identify which structure the contours belong to.

A tip here about the “ReferencedROINumber” is that it does not always the same as
the item number. For example, for the structure of “Item_2”, the ReferencedROINumber
may be “3”. In such cases, one need to check what structure the “ReferencedROINumber”
“3” corresponds to. To do that, one need to open the “rsinfo.StructureSetROISequence”
and find out which item has “ROINumber” of “3”.

st

1 point

2

nd

point

Figure 45: DICOM RT structure set contours.
Now let us look into the “ContourSequence”. Usually the “ContourSequence”
contains many items and each item stores the contours point of one frame. So if the
structure occupies 10 frames in the axial direction, there will be 10 items under
“ContourSequence” named “Item_1”, “Item_2”… “Item_10”.

In each item there is

“ContourData” which consist of an array of values. The values are the actual coordinates
in a Cartesian coordinates in three dimensions.
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The big question is that the structure contour points are defined in a real spatial
coordinate system, but the dose grid is defined as an indexed 3D matrix. How does one
correlate the relative location of a 3D dose grid to the structure contour points? To answer
this question, we must know at least the location of one voxel of the 3D matrix in a real
Cartesian coordinates in three dimensions. Then by knowing the voxel size in all three
dimensions, we can build the dose grid based on the known location of one voxel.
Fortunately, there is one voxel‟s location stored in the DICOM RT Dose file under the
field “ImagePositionPatient”. The values are the X, Y and Z coordinates of the first dose
voxel and are in the same Cartesian system as the structure set contours. The first dose
voxel is the top left corner of the first frame. The voxel size can also be found in the
DICOM files. Within one frame, the pixel size is given in the field “PixelSpacing” in
DICOM RT Dose file. To find the spacing of frames, one can calculate from the Z
coordinates of the contour points in two adjacent fames. Be sure to check the patient setup orientation (stored in “ImageOrientationPatient” in DICOM RT dose), i.e. head first
supine or foot first prone, etc., so that the structure contours won‟t be rotated or flipped
relative to the dose grid.

c) DICOM RT Plan
DICOM RT Plan is relatively simple in this study since I did not deal with the
beam sequence and the MLC control point.

It is fairly straight forward to use the

command “dicominfo” to get the essential information such as prescription dose, number
of fractions, plan name, etc.
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ABSTRACT
BEYOND THE DVH
--- SPATIAL AND BIOLOGICAL
RADIOTHERAPY TREATMENT PLANNING
by
BO ZHAO
August 2010
Advisor: Dr. Jay Burmeister
Co-Advisor: Dr. Michael C. Joiner
Major: Medical Physics
Degree: Doctor of Philosophy
Purpose: Both spatial and biological information are necessary in order to perform
true optimization of a treatment plan and for predicting clinical outcome. The goal of this
work is to develop an enhanced treatment plan evaluation tool which incorporates
biological parameters and retains spatial dose information.
Methods: A software system named SABER (Spatial And Biological Evaluation
for Radiotherapy) is developed which provides biological plan evaluation with a novel
combination of features. It incorporates hyperradiosensitivity using the induced-repair
model and applies the new concept of Dose Convolution Filter (DCF) to simulate dose
wash-out effects due to cell migration, bystander effect, and tissue motion during
treatment. Further, the concept of Spatial DVH (sDVH) is introduced to evaluate and
potentially optimize the spatial dose distribution in the target volume. Finally, generalized
equivalent uniform dose is derived from both physical dose distribution (gEUD) and EQD2
distribution (gEUD2), and the software provides three models for calculation of Tumor
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Control Probability (TCP), Normal Tissue Complication Probability (NTCP), and
Complication-free TCP (P+). TCP, NTCP and P+ are provided as a function of prescribed
dose and multi-variable TCP, NTCP and P+ plots are provided to illustrate the dependence
upon individual parameters used to calculate these quantities.
Results: By retaining both spatial and biological information about the dose
distribution, SABER is able to distinguish features of radiotherapy treatment plans not
discernible using commercial systems. Plans that have similar DVHs may have different
spatial and biological characteristics, and the application of novel tools such as sDVH and
DCF within SABER and the choice of radiobiological models may substantially change the
predicted plan metrics such as TCP and NTCP, and thus change the relative plan ranking.
The voxel-by-voxel TCP model makes it feasible to incorporate spatial variations of
clonogen densities, radiosensitivities, and fractionation sensitivities as those data become
available.
Conclusions: The SABER software incorporates both spatial and biological
information into the treatment planning process. This may significantly alter the predicted
TCP and NTCP and thus the choice of treatment plan. Thus SABER can help the planner
compare and choose more biologically optimal treatment plans and potentially predict
treatment outcome more accurately.
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